Thursday, August 8, 2024

Glial cell activation precedes neurodegeneration in the cerebellar cortex of the YG8–800 murine model of Friedreich ataxia

›
Andrés Vicente-Acosta, Saúl Herranz-Martín, María Ruth Pazos, Jorge Galán-Cruz, Mario Amores, Frida Loria, Javier Díaz-Nido, Glial cell acti...

Insulin sensitivity and insulin secretion in adults with Friedreich’s Ataxia: the role of skeletal muscle

›
Jaclyn Tamaroff, Sara Nguyen, Neil E Wilson, Darko Stefanovski, Rui Xiao, Theresa Scattergood, Christopher Capiola, Gayatri Maria Schur, Jul...

Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results

›
BALA CYNWYD, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) “We made significant achievements in our nomlabofus...

mTORC1 Signaling Inhibition Modulates Mitochondrial Function in Frataxin Deficiency

›
mTORC1 Signaling Inhibition Modulates Mitochondrial Function in Frataxin Deficiency, Madison Lehmer, Roberto Zoncu, bioRxiv 2024.08.06.60694...
Friday, August 2, 2024

Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges

›
Mishra, S., Venkatesh, M. Rare disease clinical trials in the European Union: navigating regulatory and clinical challenges. Orphanet J Rare...
Wednesday, July 31, 2024

GLP-1R mediates idebenone-reduced blood glucose in mice

›
Xin Zhao, Qingxuan Zeng, Siting Yu, Xiaochan Zhu, Bin Hu, Lijiao Deng, Yi Zhang, Yunfeng Liu,, GLP-1R mediates idebenone-reduced blood gluc...
Tuesday, July 30, 2024

Microfluidic formulation of diazoxide-loaded solid lipid nanoparticles as a Novel approach for Friedreich's ataxia treatment

›
Ilaria Arduino, Antonella Santoro, Silvia De Santis, Rosa Maria Iacobazzi, Angela Assunta Lopedota, Eleonora Paradies, Giuseppe Merla, Sara ...

Phase 2 Trial of Dimethyl Fumarate for Friedrich Ataxia

›
NeurologyLive. July 17, 2024. Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the Second Half of 2024  According to ...

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

›
NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO),  announced positive interim data of LX2006 for the trea...

Anatomical and functional analysis of the corticospinal tract in an FRDA mouse model

›
Anatomical and functional analysis of the corticospinal tract in an FRDA mouse model. Misa Nishiyama, John Kalambogias, Fumiyasu Imai, Emily...